139 related articles for article (PubMed ID: 32278731)
1. The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy.
Bargão Santos P; Lobo J; Félix A; Silva F; Manso RT; Costa JO; Lourenço B; Sequeira JP; Jerónimo C; Patel HHR; Henrique R
Urol Oncol; 2020 Oct; 38(10):794.e17-794.e27. PubMed ID: 32278731
[TBL] [Abstract][Full Text] [Related]
2. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract][Full Text] [Related]
3. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.
Wu W; Qian L; Chen X; Ding B
Int J Clin Exp Pathol; 2015; 8(10):13217-24. PubMed ID: 26722521
[TBL] [Abstract][Full Text] [Related]
5. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
Grosset AA; Ouellet V; Caron C; Fragoso G; Barrès V; Delvoye N; Latour M; Aprikian A; Bergeron A; Chevalier S; Fazli L; Fleshner N; Gleave M; Karakiewicz P; Lacombe L; Lattouf JB; van der Kwast T; Trudel D; Mes-Masson AM; Saad F;
PLoS Med; 2019 Jul; 16(7):e1002847. PubMed ID: 31265453
[TBL] [Abstract][Full Text] [Related]
6. High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma.
Wang L; Chen W; Gao L; Yang Q; Liu B; Wu Z; Wang Y; Sun Y
World J Surg Oncol; 2012 Oct; 10():212. PubMed ID: 23039915
[TBL] [Abstract][Full Text] [Related]
7. A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.
D'Alterio C; Avallone A; Tatangelo F; Delrio P; Pecori B; Cella L; Pelella A; D'Armiento FP; Carlomagno C; Bianco F; Silvestro L; Pacelli R; Napolitano M; Iaffaioli RV; Scala S
Int J Cancer; 2014 Jul; 135(2):379-90. PubMed ID: 24375277
[TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Expression Profiles of Cytoplasmic ERβ1 and Nuclear ERβ2 are Associated with Poor Outcomes following Radical Prostatectomy.
Schade GR; Holt SK; Zhang X; Song D; Wright JL; Zhao S; Kolb S; Lam HM; Levin L; Leung YK; Ho SM; Stanford JL
J Urol; 2016 Jun; 195(6):1760-6. PubMed ID: 26804755
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients.
Luo Y; Li Q; Yang X; Wei D; Feng B; Li M; Han Y; Zhao J; Lin Y; Li Q; Hou Z; Zhuang H; Jiang Y
Dis Markers; 2021; 2021():6649579. PubMed ID: 34413914
[TBL] [Abstract][Full Text] [Related]
10. A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank Specimens.
Woon DTS; Herrera-Cáceres JO; Goldberg H; Shiakh H; Whelan E; Nason G; Ajib K; Tan GH; Chandrasekar T; Alhunaidi O; Finelli A; Zlotta A; Berlin A; Diamantis E; Fleshner N
J Urol; 2020 Aug; 204(2):289-295. PubMed ID: 32068483
[TBL] [Abstract][Full Text] [Related]
11. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
[TBL] [Abstract][Full Text] [Related]
12. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
13. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.
Kang JJ; Reiter RE; Steinberg ML; King CR
Eur Urol Oncol; 2018 Oct; 1(5):378-385. PubMed ID: 31158076
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features.
Ferreira C; Lobo J; Antunes L; Lopes P; Jerónimo C; Henrique R
Virchows Arch; 2018 Oct; 473(4):443-452. PubMed ID: 30006753
[TBL] [Abstract][Full Text] [Related]
15. Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy.
Rajwa P; Schuettfort VM; Quhal F; Mori K; Katayama S; Laukhtina E; Pradere B; Motlagh RS; Mostafaei H; Grossmann NC; Aulitzky A; Paradysz A; Karakiewicz PI; Fajkovic H; Zimmermann K; Heidenreich A; Gontero P; Shariat SF
World J Urol; 2021 Oct; 39(10):3771-3779. PubMed ID: 33997919
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
Li T; Huang S; Dong M; Gui Y; Wu D
Urol Oncol; 2013 Nov; 31(8):1539-45. PubMed ID: 23089540
[TBL] [Abstract][Full Text] [Related]
17. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
18. Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?
Nguyen DP; Vertosick EA; Sharma V; Corradi RB; Vilaseca A; Takeda T; Sjoberg DD; Benfante N; Fine SW; Reuter VE; Scardino PT; Eastham JA; Karnes RJ; Touijer KA
J Urol; 2018 Jun; 199(6):1502-1509. PubMed ID: 29307681
[TBL] [Abstract][Full Text] [Related]
19. Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline.
Pompe RS; Karakiewicz PI; Tian Z; Mandel P; Steuber T; Schlomm T; Salomon G; Graefen M; Huland H; Tilki D
J Urol; 2017 Aug; 198(2):354-361. PubMed ID: 28216329
[TBL] [Abstract][Full Text] [Related]
20. A close surgical margin after radical prostatectomy is an independent predictor of recurrence.
Lu J; Wirth GJ; Wu S; Chen J; Dahl DM; Olumi AF; Young RH; McDougal WS; Wu CL
J Urol; 2012 Jul; 188(1):91-7. PubMed ID: 22578729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
